Browsing Category

65015 posts

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

HANGZHOU, China, SHANGHAI and BOSTON, June 1, 2026 /PRNewswire/ — Lynk Pharmaceuticals…
MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026

MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026

TAIPEI, June 1, 2026 /PRNewswire/ — MICROIP (TPEx: 7796), specializing in AI…

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

TAIPEI, June 1, 2026 /PRNewswire/ — Jyong Biotech Ltd. (Nasdaq: MENS) (the…

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4…
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

SUZHOU, China, June 1, 2026 /PRNewswire/ — ImmVira Group ("ImmVira") today announced…
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety…
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a…
New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026

New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026

Exploring New Business Opportunities with Global Buyers TAIPEI, June 1, 2026 /PRNewswire/…